Who We Are
Pharmaceutical raw materials and active pharmaceutical ingredients manufacturers
Tianming Pharmaceutical is a leading company in the research, development, production, and sales of new drugs. Specializing in chemical intermediates, pharmaceutical chemicals, and raw materials, we are trusted active pharmaceutical ingredient suppliers for antibiotics, cardiovascular, diabetes, anti-tumor, anti-aging, and antiviral drugs.
What We Do
Transforming Health with Premium Pharmaceutical Solutions
Advanced Drug R&D
Our team pioneers in discovering and developing new drugs, focusing on antibiotics, cardiovascular, diabetes, anti-tumor, anti-aging, and antiviral treatments.
High-Quality Manufacturing
We maintain rigorous quality control across all production processes, guaranteeing the highest standards for our chemical intermediates and pharmaceutical raw materials.
Comprehensive Global Distribution
We provide active pharmaceutical ingredients, technical consulting, collaborative R&D and other services to global customers to meet diverse market needs.
Our Products
Popular categories
Antiviral
Antiviral products and their intermediates (baloxavir fumarate, nafamostat mesylate, mupiravir, etc.)
Diabetes
Diabetes API and their intermediates (alogliptin, linagliptin, empagliflozin, etc.)
Anti-tumor
Anti-tumor API and their intermediates (ibrutinib, baricitinib, tofacitinib, etc.)
Cardiovascular
Cardiovascular API and their intermediates (LCZ696, AHU377 calcium salt, etc.)
What's News
Latest blog at Tianming
GLP-1 Intermediates: The Supply Chain Nobody Talks About (But Should)
GLP-1 intermediates market analysis: demand drivers, supply chain breakdown, peptide vs small‑molecule intermediates, and sourcing tips for buyers.
Brigatinib Manufacturer List: Takeda, Lonza & 72+ API Suppliers
Brigatinib manufacturer guide: Takeda (brand), Lonza (CDMO), and 72+ API vendors. Patent expiries: China 2026, US 2035. How to choose a reliable supplier for generic development.
Long-Term Side Effects of Ibrutinib: What the Latest Research Shows
This article summarizes 2025 latest research on ibrutinib’s long-term side effects, covering atrial fibrillation, bleeding, hypertension, infections and joint issues. It compares safety with newer BTK inhibitors and notes real-world treatment discontinuation risks.